| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/13/2001 | CA2401524A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2401398A1 Dna encoding human acid-sensing ion channel bnac4 (asic4) |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2399943A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399921A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399913A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399111A1 New aza-indolyl derivatives |
| 09/13/2001 | CA2399055A1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor |
| 09/12/2001 | EP1132472A1 Novel protein and utilization thereof |
| 09/12/2001 | EP1132389A1 New aza-indolyl derivatives for the treatment of obesity |
| 09/12/2001 | EP1132383A1 Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine |
| 09/12/2001 | EP1132376A1 Beta-amyloid protein production/secretion inhibitors |
| 09/12/2001 | EP1132098A1 Gene therapy for cerebrovascular disorders |
| 09/12/2001 | EP1132080A2 Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| 09/12/2001 | EP1131634A2 Determining the mechanism of beta-amyloid peptide generation |
| 09/12/2001 | EP1131467A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131443A2 Human hydrolase proteins |
| 09/12/2001 | EP1131436A1 Urotensins ii of mammals and their uses |
| 09/12/2001 | EP1131433A1 Members of the capsaicin/vanilloid receptor family of proteins and uses thereof |
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131425A2 Inflammation-associated genes |
| 09/12/2001 | EP1131424A2 Mutation of the parkin gene, compositions, methods and uses |
| 09/12/2001 | EP1131408A2 Cells, culture methods, and their use in autologous transplantation therapy |
| 09/12/2001 | EP1131406A2 Low oxygen culturing of central nervous system progenitor cells |
| 09/12/2001 | EP1131356A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 09/12/2001 | EP1131351A2 Peptides that modulate the interaction of b class ephrins and pdz domains |
| 09/12/2001 | EP1131350A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 09/12/2001 | EP1131349A2 Potassium channel interactors and uses therefor |
| 09/12/2001 | EP1131344A2 Retro-inversion peptides that target git transport receptors and related methods |
| 09/12/2001 | EP1131340A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 09/12/2001 | EP1131326A1 Phospholipid derivatives of non-steroidal anti-inflammatory drugs |
| 09/12/2001 | EP1131322A2 Dihydropyridine compounds and methods of use |
| 09/12/2001 | EP1131321A2 Indole derivatives and their use as serotonin receptor ligands |
| 09/12/2001 | EP1131317A1 Method for preparing (2s)-1- (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide |
| 09/12/2001 | EP1131314A1 Compounds having cytokine inhibitory activity |
| 09/12/2001 | EP1131308A1 New piperazine and piperidine compounds |
| 09/12/2001 | EP1131301A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 09/12/2001 | EP1131295A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 09/12/2001 | EP1131294A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands |
| 09/12/2001 | EP1131102A2 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e |
| 09/12/2001 | EP1131094A1 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus |
| 09/12/2001 | EP1131082A2 A method for treating tissue damaged from ischemia |
| 09/12/2001 | EP1131071A1 Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption |
| 09/12/2001 | EP1131060A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 09/12/2001 | EP1093580A4 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment |
| 09/12/2001 | EP1000065A4 Preparation of oxymorphone, oxycodone and derivatives |
| 09/12/2001 | EP0991424B1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |
| 09/12/2001 | EP0891354B1 N-aminoalkyldibenzofurancarboxamides as dopamine receptor subtype specific ligands |
| 09/12/2001 | EP0820450B1 N-substituted azaheterocyclic carboxylic acids and alkylesters thereof |
| 09/12/2001 | EP0793665B1 Heterocyclic compounds and their preparation and use |
| 09/12/2001 | EP0788349B1 Liposome composition containing selegilin |
| 09/12/2001 | EP0682514B1 Use of topical anesthetics for the manufacture of a medicament for the treatment of bronchial asthma |
| 09/12/2001 | EP0644878B1 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS |
| 09/12/2001 | CN1312812A Muscarinic agonists and antagonists |
| 09/12/2001 | CN1312810A Substituted 1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors |
| 09/12/2001 | CN1312809A N-substituted azabicycloheptane deriratives, production and use thereof |
| 09/12/2001 | CN1312808A N-Substituted azabicycloheptane derivatives, production and use thereof |
| 09/12/2001 | CN1312807A Inhibitors of glycogen synthase kinase 3 |
| 09/12/2001 | CN1312802A Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
| 09/12/2001 | CN1312800A Therapeutic biaryl derivatives |
| 09/12/2001 | CN1312719A Pharmaceutical Composition |
| 09/12/2001 | CN1312717A Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| 09/12/2001 | CN1312716A Use of optically pure (-)-norcisapride in treatment of apnea, bulimta and other disorders |
| 09/12/2001 | CN1312715A Antihypersensitive combination of valsartan and calcium channel blocker |
| 09/12/2001 | CN1312706A Medicinal aerosol for mulations |
| 09/12/2001 | CN1312372A Intocostrin regulation area and nucleotide series determination and method used thereof |
| 09/12/2001 | CN1312114A Epilepsy treating medicine powder |
| 09/12/2001 | CN1312113A Longma bone strengthening pill |
| 09/12/2001 | CN1312089A Medicine for treating depression via head acupoint osmosis |
| 09/12/2001 | CN1312088A Medicine for treating obsessional neurosis via head acupoint osmosis |
| 09/12/2001 | CN1312087A Medicine for treating neurosis via head acupoint osmosis |
| 09/12/2001 | CN1312073A New application of benzene ring pelargonate hydrochloride |
| 09/12/2001 | CN1070868C Peptides as therapeutic agents for treatment of auto-immune diseases |
| 09/12/2001 | CN1070853C 10-acyloxy-10,11-dihydrodibenz/b,f/azepine-5-carboxamides useful for treating nervous system disorders |
| 09/12/2001 | CN1070852C Process for preparing 14-o-acylate of aconite alkaloid type compounds |
| 09/12/2001 | CN1070850C Novel carbamate compounds containing thiocarbamoyl group and process for preparing same |
| 09/12/2001 | CN1070701C Pyrimidine ortriazine carboxylic acid derivatives to be used as medicaments |
| 09/12/2001 | CN1070700C Process for preparation of medicine containing flupirtine and use to combat muscular tension thereof |
| 09/11/2001 | US6288278 Benzene derived amino alcohols as drugs |
| 09/11/2001 | US6288277 Drugs, antiarthritic agants, antihistamines for treatment of asthma |
| 09/11/2001 | US6288241 Crystalline polymorphic form of 1-methyl-5-p-toluoylpyrrple-2-acetamidoacetic acid guaiacyl ester (MED 15) |
| 09/11/2001 | US6288231 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 09/11/2001 | US6288123 Therapeutic guanidines |
| 09/11/2001 | US6288109 Pyranones, method for the production and use thereof |
| 09/11/2001 | US6288104 Administering seretonin uptake inhibitors to treat depression, psychological and psychiatric disorders with an anxiety component, alcohol and drug dependence, bulimia nervosa and obsessive-compulsive disorders |
| 09/11/2001 | US6288101 Imidazoles with serotonin receptor binding activity |
| 09/11/2001 | US6288087 An extract from eupatorium purpurem, cytochrome p450 inducing compound, sugar, a source of phosphate, and one or more carriers |
| 09/11/2001 | US6288085 Piperidine derivatives for treating psychoses |
| 09/11/2001 | US6288084 Administering comounds such as 4-(4-chlorophenyl)-1-(4-(3-methoxyphenyl)-4-(3-pyridinyl)-3 -butenyl)piperidin-4-ol to treat diseases associated with aberrant leukocyte recruitment and/or activation |
| 09/11/2001 | US6288083 Chemokine receptor antagonists and methods of use therefor |
| 09/11/2001 | US6288079 Tropane-derivatives, their preparation and use |
| 09/11/2001 | US6288075 Antiepileptic agents; nervous system, brain, and cardiovascular disorders |
| 09/11/2001 | US6288069 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| 09/11/2001 | US6288068 Administering 1,4-disubstited piperidine derivative; alzheimer*s disease, cognition activators; anticholinergic agents |
| 09/11/2001 | US6288060 Corticotropin releasing factor antagonists; anxiolytic, antidepressant, antiinflammatory agents; eating disorders |
| 09/11/2001 | US6288058 Treating muscular, nervous system, psychological and gastrointestinal disorders |
| 09/11/2001 | US6288055 Analgesic agents |
| 09/11/2001 | US6288047 Lipid-based immune modulator composition |